ProjektRelax-AHF-EU – A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus…
Grunddaten
Akronym:
Relax-AHF-EU
Titel:
A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart faiure (AHF) patients
Laufzeit:
16.09.2016 bis 18.09.2017
Abstract / Kurz- beschreibung:
The aim of this study is to assess the efficacy, safety and tolerability of intravenous infusion of 30 µg/kg/day serelaxin administered for 48 hours when added to standard therapy in patients hospitalized for acute heart failure. Efficacy will be determined based on the combined primary endpoint of in-hospital worsening of heart failure requiring rescue therapy and all-cause death through day 5. Patients will be followed-up for 30 days.
The aim of this study is to generate clinical evidence, especially on the short-term period (in-hospital and at 30 days) that wil complement existing and fututre serelaxin data sets in AHF.
The aim of this study is to generate clinical evidence, especially on the short-term period (in-hospital and at 30 days) that wil complement existing and fututre serelaxin data sets in AHF.
Schlüsselwörter:
Herzkreislauferkrankungen
cardiovascular disease
Acute Heart Failure
Akute Herzinsuffizienz
Zusatztherapie (additional therapy)
Beteiligte Mitarbeiter/innen
Leiter/innen
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Lokale Einrichtungen
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute
Medizinische Fakultät
Medizinische Fakultät
Geldgeber
Nürnberg, Bayern, Deutschland